Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CYBN

Cybin Inc

Sep 13 • 04:00PM ET

0.2000

Dollar change -0.0009
Percentage change -0.45	%

Healthcare • Biotechnology • Canada • AMEX

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.14	Insider Own	8.45%	Shs Outstand	759.69M	Perf Week	-4.85%
Market Cap	152.01M	Forward P/E	-	EPS next Y	-0.11	Insider Trans	0.00%	Shs Float	695.84M	Perf Month	-24.44%
Income	-57.80M	PEG	-	EPS next Q	-0.02	Inst Own	42.04%	Short Float	2.14%	Perf Quarter	-31.03%
Sales	0.00M	P/S	-	EPS this Y	48.80%	Inst Trans	-	Short Ratio	2.75	Perf Half Y	-53.38%
Book/sh	0.27	P/B	0.73	EPS next Y	-21.58%	ROA	-47.66%	Short Interest	14.90M	Perf Year	-39.32%
Cash/sh	0.18	P/C	1.13	EPS next 5Y	-	ROE	-49.29%	52W Range	0.17 - 0.74	Perf YTD	-51.22%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-69.17%	ROI	-28.26%	52W High	-72.90%	Beta	-
Dividend TTM	-	Quick Ratio	41.70	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	15.01%	ATR (14)	0.02
Dividend Ex-Date	-	Current Ratio	41.70	EPS Y/Y TTM	25.66%	Oper. Margin	0.00%	RSI (14)	15.75	Volatility	9.84% 8.05%
Employees	-	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	3.62
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	72.14%	Payout	-	Rel Volume	0.53	Prev Close	0.20
Sales Surprise	-	EPS Surprise	35.24%	Sales Q/Q	-	Earnings	Aug 08 BMO	Avg Volume	5.42M	Price	0.20
SMA20	-18.25%	SMA50	-24.95%	SMA200	-41.97%	Trades		Volume	2,881,382	Change	-0.45%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-19-21	Downgrade	Maxim Group	Buy → Hold

Sep-04-24 07:55AM	Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-27-24 07:01PM	Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation (Business Wire)
Aug-13-24 07:30AM	Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder (Business Wire)
Aug-08-24 07:36AM	Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights (Business Wire)
Aug-07-24 07:30AM	Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference (Business Wire)
08:38AM	Loading…
Jul-08-24 08:38AM	A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update (Newsfile)
Jun-27-24 12:00PM	What Makes Cybin Inc. (CYBN) a New Buy Stock (Zacks)
Jun-26-24 07:41AM	Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights (Business Wire)
Jun-19-24 07:30AM	Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (Business Wire)
Jun-11-24 09:35AM	Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround (Zacks) +6.83%
07:30AM	Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development (Business Wire)
May-29-24 07:30AM	Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024 (Business Wire)
May-14-24 07:30AM	Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase (Business Wire)
May-06-24 08:32AM	Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones (Business Wire) +5.14%
Apr-25-24 07:30AM	Cybin to Participate at the 27th Annual Milken Institute Global Conference (Business Wire)
07:30AM	Loading…
Apr-18-24 07:30AM	Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry (Business Wire)
Apr-16-24 07:30AM	Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder (Business Wire)
Apr-10-24 07:30AM	Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference (Business Wire) -5.90%
Mar-19-24 11:53AM	Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million (Business Wire)
Mar-18-24 07:30AM	Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas (Business Wire)
Mar-15-24 07:30AM	Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder (Business Wire) +7.23%
Mar-14-24 07:30AM	Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design (Business Wire)
Mar-13-24 07:00AM	Announces Oversubscribed Private Placement of U.S. $150 Million (Business Wire)
06:00AM	Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder (Business Wire)
Mar-12-24 10:37PM	Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003 (Business Wire) +10.28%
Feb-27-24 07:30AM	Cybin to Present at the TD Cowen 44th Annual Health Care Conference (Business Wire)
Feb-14-24 07:45AM	Cybin Reports Third Quarter Financial Results and Recent Business Highlights (Business Wire)
Feb-07-24 07:30AM	Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program (Business Wire) -9.06%
Jan-28-24 05:02PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jan-24-24 09:00AM	How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition (PR Newswire)
07:30AM	Loading…
Jan-23-24 07:30AM	Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder (Business Wire)
Jan-08-24 07:34AM	Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028 (Business Wire)
Jan-04-24 07:32AM	Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs (Business Wire)
Dec-06-23 07:30AM	Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program (Business Wire)
Dec-05-23 07:30AM	Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results (Business Wire)
Nov-30-23 07:30AM	Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses (Business Wire) -6.03%
Nov-20-23 07:30AM	Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City (Business Wire)
Nov-16-23 07:30AM	Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023 (Business Wire)
Nov-15-23 07:30AM	Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting (Business Wire)
Nov-14-23 07:16PM	Cybin Reports Second Quarter Financial Results and Recent Business Highlights (Business Wire)
01:00PM	Cybin Announces Closing of Offering of Units Led by One of the Companys Largest Institutional Shareholders (Business Wire)
Nov-10-23 08:13AM	Canadian Investment Regulatory Organization Trade Resumption - CYBN (PR Newswire) -15.31%
08:05AM	Canadian Investment Regulatory Organization Trading Halt - CYBN (PR Newswire)
08:03AM	Cybin Announces up to US$64 Million Offering of Units (Business Wire)
Nov-03-23 07:40AM	Cybin to Participate at the 2023 Milken Institute Future of Health Summit (Business Wire)
Nov-01-23 03:32PM	Breakthrough Results: Cybin's CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder, Achieving Primary Efficacy Milestone and Delivering Prompt Relief from Depression Symptoms with a Single Dose - Comprehensive Topline Data Anticipated by Q4 2023 (Newsfile) -11.75%
07:30AM	Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline (Business Wire)
Oct-31-23 09:00AM	Cybin Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose - Full Topline Data on Track for Q4 2023 (PR Newswire) +6.71%
07:45AM	Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose (Business Wire)
Oct-29-23 05:17PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Oct-26-23 07:30AM	Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs (Business Wire) +12.61%
Oct-25-23 07:30AM	Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program (Business Wire) +11.10%
Oct-23-23 07:33AM	Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics (Business Wire)
Oct-17-23 05:35PM	Small Pharma Obtains Final Order Approving Arrangement (Business Wire) -6.22% -5.57%
Oct-12-23 05:00PM	Cybin Announces Results of Annual and Special Meeting of Shareholders (Business Wire) -5.06%
Oct-06-23 07:30AM	Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit (Business Wire) +5.42%
Oct-04-23 07:30AM	Cybin to Present at the Jefferies Inaugural Biotech CNS/Neuro Summit (Business Wire)
Oct-03-23 07:30AM	Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder (Business Wire) -5.40%
Sep-27-23 07:30AM	Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder (Business Wire) -5.64%
Sep-26-23 07:30AM	Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial (Business Wire) -7.99%
Sep-25-23 07:30AM	Cybin to Participate in the Cantor Global Healthcare Conference (Business Wire) +14.62%
Sep-21-23 05:00PM	Cybin Announces Date of Annual and Special Meeting of Shareholders (Business Wire) +15.13% +12.24%
07:30AM	Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder (Business Wire)
Sep-05-23 07:30AM	Cybin Announces Grant of U.S. Patent Covering Deuterated Tryptamines (Business Wire)
Aug-28-23 01:23PM	Cybin to Acquire Small Pharma Inc. (Newsfile) +5.10%
10:57AM	Canadian Investment Regulatory Organization Trade Resumption - CYBN (PR Newswire)
09:22AM	Canadian Investment Regulatory Organization Trading Halt - CYBN (PR Newswire)
Aug-23-23 09:37PM	Cybin Announces Renewed At-The-Market Equity Program of up to US$35 Million (Business Wire)
Aug-21-23 01:40PM	Cybin Inc protects IP with granting of 2nd US Patent for its deuterated analog programs (News Direct)
Aug-17-23 07:30AM	Cybin Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial (Business Wire)
Aug-15-23 07:52AM	Cybin Announces Grant of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog in its CYB003 Program (Business Wire)
Aug-14-23 07:30AM	Cybin Reports First Quarter Financial Results and Recent Business Highlights (Business Wire)
Aug-04-23 09:46AM	Cybin Announces Closing of Overnight Marketed Public Offering of Units (Business Wire) +10.75%
Aug-02-23 07:30AM	Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder (Business Wire) -8.52%
Aug-01-23 09:32AM	Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Units (Business Wire) -20.73%
Jul-31-23 06:29PM	Cybin Announces Overnight Marketed Public Offering of Units (Business Wire)
Jul-27-23 07:30AM	Cybin to Participate in the Canaccord Genuity 43rd Annual Growth Conference (Business Wire)
Jul-26-23 07:30AM	Cybin Partners With Worldwide Clinical Trials to Support Future Clinical Development of CYB003 in Major Depressive Disorder (Business Wire)
Jul-24-23 07:55AM	Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder (PR Newswire)
Jul-20-23 05:01PM	Cybin Announces Publication of Sponsored Feasibility Study Validating Kernels Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain (Business Wire) -5.08%
08:00AM	Kernel's Revolutionary Neuroimaging Technology, Flow1, Validated in Published Feasibility Study on Measuring Psychedelic Effects (Business Wire)
Jul-17-23 08:44AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jul-12-23 07:30AM	Cybin Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARKCT (Business Wire) +9.09%
Jun-30-23 07:30AM	Cybin to Participate in PSYCH Symposium London 2023 (Business Wire)
Jun-29-23 05:00PM	Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer (Business Wire) +11.52%
Jun-27-23 05:00PM	Cybin Inc. Reports Fiscal Year 2023 Financial Results and Recent Business Highlights (Business Wire) +10.00%
07:30AM	Cybin Announces Appointment of Sanford R. Climan as Strategic Advisor (Business Wire)
Jun-21-23 07:30AM	Cybin to Participate in the 2023 MAPS Psychedelic Science Conference (Business Wire) +5.91%
Jun-15-23 07:30AM	Cybin to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference (Business Wire) +10.44%
Jun-08-23 07:30AM	Cybin Inc. Provides Corporate Update (Business Wire)
Jun-05-23 07:30AM	Cybin Announces Scientific Management Transition Following Achievement of Final Adelia Milestones (Business Wire)
Jun-01-23 07:30AM	Cybin to Present at the Jefferies Healthcare Conference (Business Wire)
May-30-23 05:46PM	Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund (Business Wire)
May-24-23 07:30AM	Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial (Business Wire)
May-09-23 07:30AM	Cybin Announces Last Subject Dosed in Part B of its Phase 1 CYB004-E Trial (Business Wire)
Apr-28-23 08:00AM	Cybin to Participate at the 26th Annual Milken Institute Global Conference (Business Wire) +9.35%
Apr-12-23 07:30AM	Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy (Business Wire)
Mar-08-23 07:30AM	Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference (Business Wire)
Mar-02-23 04:23PM	Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference (Business Wire)
Feb-28-23 07:30AM	Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program (Business Wire) -7.14%

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CYBN

Cybin Inc

Upgrade your FINVIZ experience